Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient

Risperidone is a second generation "atypical" antipsychotic that exhibits its clinical effects through a combined effort of risperidone and its active metabolite, 9-hydroxyrisperidone (9-OHR), otherwise known as paliperidone. Risperidone is hepatically metabolized by the cytochrome P450 2D...

Full description

Saved in:
Bibliographic Details
Published in:The mental health clinician 2023-06, Vol.13 (3), p.159-162
Main Authors: Reynolds, Jamie, Gramlich, Nicole
Format: Article
Language:English
Subjects:
Case Reports
cyp2d6 inhibitor
drug interactions
risperidone
terbinafine
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2269-a44df82241b2771ebd5cf8c571dd088037e46b82bde2b46e3a53448e01a682dc3
container_end_page 162
container_issue 3
container_start_page 159
container_title The mental health clinician
container_volume 13
creator Reynolds, Jamie
Gramlich, Nicole
description Risperidone is a second generation "atypical" antipsychotic that exhibits its clinical effects through a combined effort of risperidone and its active metabolite, 9-hydroxyrisperidone (9-OHR), otherwise known as paliperidone. Risperidone is hepatically metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme into 9-OHR. Significant interference with the metabolism of risperidone may lead to clinical consequences for patients via alterations in the ratio of the parent compound and active metabolite. This patient case reports 1 example of how a drug interaction could contribute to delayed response to a medication increase after psychiatric decompensation. A forensic psychiatric patient was transitioned from oral risperidone to risperidone microspheres long-acting injectable and had worsening of symptoms, necessitating an increased dose of the injection. This increase in symptoms may have been prolonged by addition of a CYP2D6 inhibitor, terbinafine. The changes in clinical symptoms correlate with medication concentrations that were drawn before terbinafine was started, during terbinafine therapy, and after terbinafine was discontinued.
doi_str_mv 10.9740/mhc.2023.06.159
format article
fullrecord <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_76e8c823be164573b973f513bbfa9be5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_76e8c823be164573b973f513bbfa9be5</doaj_id><sourcerecordid>37448829</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2269-a44df82241b2771ebd5cf8c571dd088037e46b82bde2b46e3a53448e01a682dc3</originalsourceid><addsrcrecordid>eNpVkV1rXCEQhqW0NCHJde-Kf2A3fh31XJUS-hEI9Ca9llHnnDWc1UXPFvLva7JtSK4cdd5nGB5CPnG2HY1i1_td2Aom5JbpLR_Gd-RccG03o2Hj-1f1Gblq7YExJhhXgx4_kjNplLJWjOek3GP1KcOUMlLIkdbUDlhTLP0e63GmKa9YIaypZBpKXmvyxzXlma6FhiXlFGChYQd5xtabKdCpVMwtBXpoj2GXoEd6DWvCvF6SDxMsDa_-nRfk9_dv9zc_N3e_ftzefL3bBCH0uAGl4mSFUNwLYzj6OITJhsHwGJm1TBpU2lvhIwqvNEoYZF8JGQdtRQzygtyeuLHAgzvUtIf66Aok9_xQ6uygriks6IxGG6yQHrlWg5F-NHIauPR-gtHj0FlfTqzD0e8xhr5GheUN9O1PTjs3lz-OMymNtbwTrk-EUEtrFaeXMGfuyaXrLt2TS8e06y574vPrmS_9_83Jv_NUndY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient</title><source>PubMed Central (Open access)</source><source>EZB Electronic Journals Library</source><creator>Reynolds, Jamie ; Gramlich, Nicole</creator><creatorcontrib>Reynolds, Jamie ; Gramlich, Nicole</creatorcontrib><description>Risperidone is a second generation "atypical" antipsychotic that exhibits its clinical effects through a combined effort of risperidone and its active metabolite, 9-hydroxyrisperidone (9-OHR), otherwise known as paliperidone. Risperidone is hepatically metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme into 9-OHR. Significant interference with the metabolism of risperidone may lead to clinical consequences for patients via alterations in the ratio of the parent compound and active metabolite. This patient case reports 1 example of how a drug interaction could contribute to delayed response to a medication increase after psychiatric decompensation. A forensic psychiatric patient was transitioned from oral risperidone to risperidone microspheres long-acting injectable and had worsening of symptoms, necessitating an increased dose of the injection. This increase in symptoms may have been prolonged by addition of a CYP2D6 inhibitor, terbinafine. The changes in clinical symptoms correlate with medication concentrations that were drawn before terbinafine was started, during terbinafine therapy, and after terbinafine was discontinued.</description><identifier>ISSN: 2168-9709</identifier><identifier>EISSN: 2168-9709</identifier><identifier>DOI: 10.9740/mhc.2023.06.159</identifier><identifier>PMID: 37448829</identifier><language>eng</language><publisher>United States: American Association of Psychiatric Pharmacists</publisher><subject>Case Reports ; cyp2d6 inhibitor ; drug interactions ; risperidone ; terbinafine</subject><ispartof>The mental health clinician, 2023-06, Vol.13 (3), p.159-162</ispartof><rights>2023 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists.</rights><rights>2023 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2269-a44df82241b2771ebd5cf8c571dd088037e46b82bde2b46e3a53448e01a682dc3</cites><orcidid>0000-0002-1284-6519 ; 0000-0002-3241-2451</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337881/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337881/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37448829$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reynolds, Jamie</creatorcontrib><creatorcontrib>Gramlich, Nicole</creatorcontrib><title>Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient</title><title>The mental health clinician</title><addtitle>Ment Health Clin</addtitle><description>Risperidone is a second generation "atypical" antipsychotic that exhibits its clinical effects through a combined effort of risperidone and its active metabolite, 9-hydroxyrisperidone (9-OHR), otherwise known as paliperidone. Risperidone is hepatically metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme into 9-OHR. Significant interference with the metabolism of risperidone may lead to clinical consequences for patients via alterations in the ratio of the parent compound and active metabolite. This patient case reports 1 example of how a drug interaction could contribute to delayed response to a medication increase after psychiatric decompensation. A forensic psychiatric patient was transitioned from oral risperidone to risperidone microspheres long-acting injectable and had worsening of symptoms, necessitating an increased dose of the injection. This increase in symptoms may have been prolonged by addition of a CYP2D6 inhibitor, terbinafine. The changes in clinical symptoms correlate with medication concentrations that were drawn before terbinafine was started, during terbinafine therapy, and after terbinafine was discontinued.</description><subject>Case Reports</subject><subject>cyp2d6 inhibitor</subject><subject>drug interactions</subject><subject>risperidone</subject><subject>terbinafine</subject><issn>2168-9709</issn><issn>2168-9709</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkV1rXCEQhqW0NCHJde-Kf2A3fh31XJUS-hEI9Ca9llHnnDWc1UXPFvLva7JtSK4cdd5nGB5CPnG2HY1i1_td2Aom5JbpLR_Gd-RccG03o2Hj-1f1Gblq7YExJhhXgx4_kjNplLJWjOek3GP1KcOUMlLIkdbUDlhTLP0e63GmKa9YIaypZBpKXmvyxzXlma6FhiXlFGChYQd5xtabKdCpVMwtBXpoj2GXoEd6DWvCvF6SDxMsDa_-nRfk9_dv9zc_N3e_ftzefL3bBCH0uAGl4mSFUNwLYzj6OITJhsHwGJm1TBpU2lvhIwqvNEoYZF8JGQdtRQzygtyeuLHAgzvUtIf66Aok9_xQ6uygriks6IxGG6yQHrlWg5F-NHIauPR-gtHj0FlfTqzD0e8xhr5GheUN9O1PTjs3lz-OMymNtbwTrk-EUEtrFaeXMGfuyaXrLt2TS8e06y574vPrmS_9_83Jv_NUndY</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Reynolds, Jamie</creator><creator>Gramlich, Nicole</creator><general>American Association of Psychiatric Pharmacists</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-1284-6519</orcidid><orcidid>https://orcid.org/0000-0002-3241-2451</orcidid></search><sort><creationdate>202306</creationdate><title>Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient</title><author>Reynolds, Jamie ; Gramlich, Nicole</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2269-a44df82241b2771ebd5cf8c571dd088037e46b82bde2b46e3a53448e01a682dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Case Reports</topic><topic>cyp2d6 inhibitor</topic><topic>drug interactions</topic><topic>risperidone</topic><topic>terbinafine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reynolds, Jamie</creatorcontrib><creatorcontrib>Gramlich, Nicole</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>The mental health clinician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reynolds, Jamie</au><au>Gramlich, Nicole</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient</atitle><jtitle>The mental health clinician</jtitle><addtitle>Ment Health Clin</addtitle><date>2023-06</date><risdate>2023</risdate><volume>13</volume><issue>3</issue><spage>159</spage><epage>162</epage><pages>159-162</pages><issn>2168-9709</issn><eissn>2168-9709</eissn><abstract>Risperidone is a second generation "atypical" antipsychotic that exhibits its clinical effects through a combined effort of risperidone and its active metabolite, 9-hydroxyrisperidone (9-OHR), otherwise known as paliperidone. Risperidone is hepatically metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme into 9-OHR. Significant interference with the metabolism of risperidone may lead to clinical consequences for patients via alterations in the ratio of the parent compound and active metabolite. This patient case reports 1 example of how a drug interaction could contribute to delayed response to a medication increase after psychiatric decompensation. A forensic psychiatric patient was transitioned from oral risperidone to risperidone microspheres long-acting injectable and had worsening of symptoms, necessitating an increased dose of the injection. This increase in symptoms may have been prolonged by addition of a CYP2D6 inhibitor, terbinafine. The changes in clinical symptoms correlate with medication concentrations that were drawn before terbinafine was started, during terbinafine therapy, and after terbinafine was discontinued.</abstract><cop>United States</cop><pub>American Association of Psychiatric Pharmacists</pub><pmid>37448829</pmid><doi>10.9740/mhc.2023.06.159</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-1284-6519</orcidid><orcidid>https://orcid.org/0000-0002-3241-2451</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-9709
ispartof The mental health clinician, 2023-06, Vol.13 (3), p.159-162
issn 2168-9709
2168-9709
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_76e8c823be164573b973f513bbfa9be5
source PubMed Central (Open access); EZB Electronic Journals Library
subjects Case Reports
cyp2d6 inhibitor
drug interactions
risperidone
terbinafine
title Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A57%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Terbinafine%20and%20risperidone%20drug%20interaction%20contributing%20to%20clinical%20changes%20in%20a%20forensic%20psychiatric%20patient&rft.jtitle=The%20mental%20health%20clinician&rft.au=Reynolds,%20Jamie&rft.date=2023-06&rft.volume=13&rft.issue=3&rft.spage=159&rft.epage=162&rft.pages=159-162&rft.issn=2168-9709&rft.eissn=2168-9709&rft_id=info:doi/10.9740/mhc.2023.06.159&rft_dat=%3Cpubmed_doaj_%3E37448829%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2269-a44df82241b2771ebd5cf8c571dd088037e46b82bde2b46e3a53448e01a682dc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/37448829&rfr_iscdi=true